#1 Clinical Trials Search in Europe

Rifamycin Sodium

Rifamycin Sodium, a broad-spectrum antibiotic, is being investigated in several clinical trials for its efficacy in treating various gastrointestinal disorders. These trials aim to evaluate the drug’s potential in managing conditions such as traveler’s diarrhea, uncomplicated diverticulitis, and diarrhea-predominant irritable bowel syndrome (IBS-D). The studies focus on different formulations, dosages, and patient populations to determine the optimal use of Rifamycin Sodium in these conditions.

Table of Contents

What is Rifamycin Sodium?

Rifamycin Sodium, also known as Rifamycin SV-MMX, is an antibiotic medication used to treat various gastrointestinal conditions[1]. It belongs to a class of drugs called rifamycins, which are known for their ability to fight bacterial infections. The MMX in its name stands for Multi-Matrix System, which is a special formulation designed to release the medication in a controlled manner throughout the digestive system[5].

Uses of Rifamycin Sodium

Rifamycin Sodium is primarily used to treat the following conditions:

  • Traveler’s Diarrhea: This is a common illness that affects people visiting areas with poor sanitation. Rifamycin Sodium has been studied for its effectiveness in treating traveler’s diarrhea in both adults and children[1][4].
  • Acute Uncomplicated Diverticulitis: This is a condition where small pouches in the lining of the colon become inflamed or infected. Research has been conducted to evaluate Rifamycin Sodium’s efficacy in treating this condition[2].
  • Irritable Bowel Syndrome with Diarrhea (IBS-D): Studies have explored the use of Rifamycin Sodium in managing symptoms of IBS-D, which is characterized by abdominal pain and frequent, loose stools[3].

How Rifamycin Sodium Works

Rifamycin Sodium works by targeting and eliminating harmful bacteria in the intestines that cause diarrhea and other gastrointestinal symptoms. The special MMX formulation allows the medication to be released gradually as it moves through the digestive system, maximizing its effectiveness[5].

Dosage and Administration

The dosage of Rifamycin Sodium can vary depending on the condition being treated and the age of the patient. Here are some examples from clinical trials:

  • For traveler’s diarrhea in adults: 400 mg (two 200 mg tablets) twice daily for 3 days[1].
  • For traveler’s diarrhea in children aged 12-17: 400 mg (two 200 mg tablets) twice daily for 3 days[1].
  • For traveler’s diarrhea in children aged 6-11: 100 mg (two 50 mg tablets) twice daily for 3 days[4].
  • For IBS-D in adults: Various dosages have been studied, including 600 mg three times daily or 600 mg twice daily[3].

It’s important to note that these dosages are from clinical trials and may not reflect the final approved dosages. Always follow your doctor’s instructions when taking Rifamycin Sodium.

Potential Side Effects

As with any medication, Rifamycin Sodium may cause side effects. Clinical trials have monitored for various adverse events, including:

  • Gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain)
  • Changes in stool consistency
  • Fever
  • Changes in blood and urine tests

It’s important to report any unusual symptoms to your healthcare provider while taking this medication[1][3].

Ongoing Research

Rifamycin Sodium is still being studied for various uses and in different patient populations. Some areas of ongoing research include:

  • Its effectiveness in treating traveler’s diarrhea in children of different age groups[1][4].
  • Its potential use in managing symptoms of irritable bowel syndrome with diarrhea (IBS-D)[3].
  • Its safety and efficacy in treating acute uncomplicated diverticulitis[2].
  • Its use in preventing tuberculosis in kidney transplant recipients[6].

These ongoing studies aim to provide more information about the safety and effectiveness of Rifamycin Sodium in various conditions and patient groups.

Condition Drug Formulation Dosage Study Population Primary Outcomes
Traveler’s Diarrhea Rifamycin SV-MMX 400 mg twice daily Children (12-17 years) Clinical cure rate
Traveler’s Diarrhea Rifamycin SV-MMX 100 mg twice daily Children (6-11 years) Clinical cure rate
Uncomplicated Diverticulitis Rifamycin SV-MMX 400 mg twice daily or 600 mg three times daily Adults Treatment success rate
IBS-D Rifamycin SV-MMX 600 mg two or three times daily Adults Relief from abdominal pain and improved stool consistency

FAQ

  • What is Rifamycin Sodium used for in these clinical trials? Rifamycin Sodium is being studied for its effectiveness in treating various gastrointestinal disorders, including traveler's diarrhea in both adults and children, uncomplicated diverticulitis, and diarrhea-predominant irritable bowel syndrome (IBS-D).
  • How is Rifamycin Sodium administered in these trials? The drug is administered orally in tablet form, with different dosages and frequencies depending on the specific trial and condition being studied. For example, in some trials, it's given as 400 mg twice daily, while in others, it's 600 mg two or three times daily.
  • What are the main outcomes being measured in these trials? The trials are measuring various outcomes, including time to last unformed stool, clinical cure rates, relief from abdominal pain, improvement in stool consistency, and overall symptom relief. Safety outcomes are also being monitored through adverse event reporting and laboratory tests.
  • Are there any special formulations of Rifamycin Sodium being used? Yes, many of the trials are using a special formulation called Rifamycin SV-MMX, which stands for Multi-Matrix System. This formulation is designed to deliver the drug more effectively to the intestines.
  • How long do the treatments typically last in these trials? The treatment duration varies depending on the condition being studied. For traveler's diarrhea, the treatment typically lasts 3 days (72 hours), while for conditions like IBS-D, the treatment period can be up to 12 weeks.

Ongoing Clinical Trials on Rifamycin Sodium

  • Study on the Effectiveness and Safety of Vedolizumab for Children with Chronic Pouchitis Using a Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Croatia Czechia Denmark Greece Italy +2

  • Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

    Not recruiting

    2 1
    Investigated drugs:
    Bulgaria Estonia Hungary Latvia Lithuania Poland +1

Glossary

  • Rifamycin Sodium: A broad-spectrum antibiotic being studied for its effectiveness in treating various gastrointestinal disorders.
  • MMX (Multi-Matrix System): A special drug delivery system used in some formulations of Rifamycin to enhance its effectiveness in reaching the intestines.
  • Traveler's Diarrhea: A digestive tract disorder commonly affecting travelers, characterized by loose stools and abdominal cramps, usually caused by consuming contaminated food or water.
  • Uncomplicated Diverticulitis: A condition where small, bulging pouches (diverticula) in the digestive tract become inflamed or infected, but without serious complications.
  • IBS-D (Diarrhea-predominant Irritable Bowel Syndrome): A type of irritable bowel syndrome where diarrhea is the predominant symptom, along with abdominal pain and discomfort.
  • Clinical Cure: In these trials, it often refers to the resolution of symptoms such as reduced frequency of loose stools, absence of fever, and improvement in other related symptoms.
  • TLUS (Time to Last Unformed Stool): A measure used in some trials, defined as the time interval between the first dose of the study drug and the last loose stool passed before clinical cure is achieved.
  • Oral Rehydration Therapy (ORT): A type of fluid replacement used to prevent or treat dehydration, especially due to diarrhea.
  • Placebo: An inactive substance used in clinical trials as a control to compare with the active drug being tested.
  • Double-blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.

References

  1. https://clinicaltrials.gov/study/NCT04027894
  2. https://clinicaltrials.gov/study/NCT01847664
  3. https://clinicaltrials.gov/study/NCT03099785
  4. https://clinicaltrials.gov/study/NCT04026984
  5. https://clinicaltrials.gov/study/NCT01142089
  6. https://clinicaltrials.gov/study/NCT05588492